The largest database of trusted experimental protocols

Bardoxolone methyl bm

Manufactured by Merck Group
Sourced in United States

Bardoxolone methyl (BM) is a synthetic triterpenoid compound developed by Reata Pharmaceuticals and licensed to Kyowa Kirin for clinical development and commercialization. BM is a nuclear factor erythroid 2-related factor 2 (Nrf2) activator that has been studied for its potential therapeutic effects in various disease conditions.

Automatically generated - may contain errors

2 protocols using bardoxolone methyl bm

1

Intrathecal Administration of Bioactive Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following compounds were used in our experiments: fisetin (F; Cayman, Ann Arbor, MI, USA), peimine (P; Sigma‒Aldrich, St Louis, USA), artemisinin (Ar; Sigma‒Aldrich, St. Louis, MI, USA), astaxanthin (A; Sigma‒Aldrich, St Louis, USA), bardoxolone methyl (BM, Sigma‒Aldrich, St. Louis, MI, USA), 740 Y-P (7; Med Chem Express, Monmouth Junction, NJ, USA), morphine hydrochloride (M; Fagron, Krakow, Poland), buprenorphine (B; Polfa S.A., Warsaw, Poland) and oxycodone hydrochloride (O; Molteni Farmaceutici, Scandicci, Italy). All of these substances were administered via intrathecal injection (i.t.), a standard procedure in our laboratory [109 (link),111 (link)]. It is performed by using a Hamilton syringe with a thin needle in accordance with instructions described previously [112 (link)]. The injections were performed in the lumbar segment of the spinal cord (between the L5 and L6 vertebrae) with a volume of 5 µL, and the tail reflex was an indicator of correct administration.
+ Open protocol
+ Expand
2

Nasal Epithelial Cell Transfection

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human NPC cell lines CNE1, CNE2 and HNE1 were obtained from the Cellbank of Chinese Academy of Sciences (Shanghai, China), maintained at 37°C with 5% CO2 in Dulbecco's Modified Eagle Medium (Invitrogen, California, USA) and supplemented with 10% fetal bovine serum (FBS; Gibco, USA). The human nasal epithelial cell line RPMI2650 was obtained from ATCC (USA) and cultured in minimum essential medium (Gibco, USA) supplemented with 10% FBS at 37°C with 5% CO2.
The CNE1 and HNE1 cells were transfected by pcDNA3.0 plasmid (NC), pcDNA3.0-LAMB3 (LAMB3), shNC, shLAMB-1# or shLAMB-2# (Ribobio, China) following the manufacturer’s standard protocol.
For co-transfection, the CNE1 and HNE1 cells were co-transfected with shLAMB-2# or shNC and shFOXO3 following the manufacturer’s standard protocol.
To activate NRF2 signaling pathway, the cells were pretreated with 10 nM bardoxolone methyl (BM; Sigma-Aldrich, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!